Mirae Asset Global ETFs Holdings’s Revance Therapeutics, Inc. RVNC Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-59,629	Closed	-$181K	–	3104
2024 Q4	$181K	Buy	59,629 +2,584	+5%	+$11.3K	﹤0.01%	2434
2024 Q3	$296K	Buy	57,045 +13,116	+30%	+$65.2K	﹤0.01%	2170
2024 Q2	$113K	Buy	+43,929	New	+$150K	﹤0.01%	2512

Other funds holding RVNC

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Mirae Asset Global ETFs Holdings's RVNC Position: Q1 2025 in Review

Mirae Asset Global ETFs Holdings sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 59,629 shares — an estimated $181K sold.

Mirae Asset Global ETFs Holdings first reported a position in RVNC in Q2 2024 and held it in 3 quarters. The position peaked at $296K in Q3 2024. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

Mirae Asset Global ETFs Holdings reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
Mirae Asset Global ETFs Holdings sold 59,629 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $181K.
Mirae Asset Global ETFs Holdings first reported a position in Revance Therapeutics, Inc. in Q2 2024 and held it in 3 quarters.
Mirae Asset Global ETFs Holdings's Revance Therapeutics, Inc. position peaked at $296K in Q3 2024.
1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q1 2025, filed 15 May 2025.